Non-alcoholic steatohepatitis (MASH, formerly NASH) is a progressive disease that takes years to develop in humans and involves an intricate interplay of multiple liver cell types, impaired liver functionality, and disrupted signaling.
InSphero Senior Application Scientist Dr. Sue Grepper presents a versatile platform for screening and testing MASH therapies using pathophysiologically relevant, disease-tunable 3D in vitro human models.
You will learn how our models can be applied to:
- Recapitulate hallmarks of MASH pathology, such as fatty liver, inflammation and fibrosis
- Assess compound and treatment effects on MASH with scalable, quantitative endpoints
- Confirm perturbation of key pathways involved in disease progression